Literature DB >> 12099957

Cardiovascular risk profile assessment in glucose-intolerant Asian individuals--an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia).

.   

Abstract

AIMS: To assess the cardiovascular (CVD) risk factor profile in individuals with diabetes and impaired glucose tolerance (IGT) identified by a one-step (fasting plasma glucose (FPG)) or a two-step strategy (including an oral glucose tolerance test (OGTT) in subjects with impaired fasting glucose (IFG)) as recommended by the World Health Organization (WHO).
METHODS: Twelve population-based studies in six countries (17 512 subjects, age 30-89 years, without known diabetes, with OGTT (fasting and 2-h plasma glucose (2-h PG))). Age, gender, and centre-adjusted means of CVD risk factors were compared according to the level of glucose intolerance.
RESULTS: Diabetes was found in 1270 individuals and IFG or IGT in 3158. In the diabetic group 55.1% had a FPG > or = 7.0 mmol/l (range between countries 36.2-67.0%), 20.5% were identified through the stepwise strategy (range 0-32%), while 24.4% would remain undiagnosed (FPG < 6.1 mmol/l) (range 9.0-40.0%). The two-step strategy identified 60-91% of all newly diagnosed diabetic subjects with 5-12% of the population requiring an OGTT. Mean body mass index (BMI), blood pressure, and total cholesterol did not differ between diabetic individuals diagnosed by FPG or OGTT. The step-wise strategy identified < 50% of the subjects with impaired glucose regulation, and the cardiovascular risk profile (BMI, blood pressure, and cholesterol) did not differ between those identified and those not identified in the screening process.
CONCLUSIONS: Applying an OGTT in subjects with IFG will fail to detect every fourth diabetic individual and every second individual with impaired glucose regulation. Individuals not diagnosed had a cardiovascular risk profile identical to those identified in the diagnostic process. Lower thresholds for an OGTT may be necessary in Asian populations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12099957     DOI: 10.1046/j.1464-5491.2002.00735.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  13 in total

1.  Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus.

Authors:  Noriko Kodani; Yoshifumi Saisho; Kumiko Tanaka; Toshihide Kawai; Hiroshi Itoh
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

2.  Pravastatin improves postprandial endothelial dysfunction and hemorheological deterioration in patients with effort angina pectoris.

Authors:  Tomio Umemoto; Takanori Yasu; Kenshiro Arao; Nahoko Ikeda; Yasuto Horie; Hiroyuki Sugimura; Masanobu Kawakami; Hideo Fujita; Shin-Ichi Momomura
Journal:  Heart Vessels       Date:  2017-04-10       Impact factor: 2.037

Review 3.  Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.

Authors:  Y G Kim; S Hahn; T J Oh; S H Kwak; K S Park; Y M Cho
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

4.  Diabetes prevalence and body mass index differ by ethnicity: the Multiethnic Cohort.

Authors:  Gertraud Maskarinec; Andrew Grandinetti; Grace Matsuura; Sangita Sharma; Marjorie Mau; Brian E Henderson; Laurence N Kolonel
Journal:  Ethn Dis       Date:  2009       Impact factor: 1.847

5.  Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas.

Authors:  Sheng-Hwu Hsieh; Kuang-Chung Shih; Chien-Wen Chou; Chih-Hsun Chu
Journal:  Acta Diabetol       Date:  2010-10-21       Impact factor: 4.280

6.  Optimal cut-off points of fasting plasma glucose for two-step strategy in estimating prevalence and screening undiagnosed diabetes and pre-diabetes in Harbin, China.

Authors:  Chundan Bao; Dianfeng Zhang; Bo Sun; Li Lan; Wenxiu Cui; Guohua Xu; Conglan Sui; Yibaina Wang; Yashuang Zhao; Jian Wang; Hongyuan Li
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 7.  The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea.

Authors:  Seungjoon Oh; Suk Chon; Kyu Jeong Ahn; In-Kyung Jeong; Byung-Joon Kim; Jun Goo Kang
Journal:  Diabetes Metab J       Date:  2015-06       Impact factor: 5.376

Review 8.  The clinical application of linagliptin in Asians.

Authors:  Chu-Qing Cao; Yu-Fei Xiang; Zhi-Guang Zhou
Journal:  Ther Clin Risk Manag       Date:  2015-09-16       Impact factor: 2.423

9.  Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.

Authors:  Yan-Rong Li; Sung-Sheng Tsai; Dong-Yi Chen; Szu-Tah Chen; Jui-Hung Sun; Hung-Yu Chang; Miaw-Jene Liou; Tien-Hsing Chen
Journal:  Cardiovasc Diabetol       Date:  2018-01-04       Impact factor: 9.951

10.  Evaluation of the Japanese Metabolic Syndrome Risk Score (JAMRISC): a newly developed questionnaire used as a screening tool for diagnosing metabolic syndrome and insulin resistance in Japan.

Authors:  Ce Tan; Yutaka Sasagawa; Ken-Ichi Kamo; Takehiro Kukitsu; Sayaka Noda; Kazuma Ishikawa; Natsumi Yamauchi; Takashi Saikawa; Takanori Noro; Hajime Nakamura; Fumihiko Takahashi; Fumihiro Sata; Mitsuhiro Tada; Yasuo Kokai
Journal:  Environ Health Prev Med       Date:  2016-10-03       Impact factor: 3.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.